查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631500

稀有生物標記檢體採集和穩定市場規模、佔有率、趨勢分析報告（按生物標記、最終用途、地區、細分市場預測），2025 年至 2030 年

Rare Biomarkers Specimen Collection And Stabilization Market Size, Share & Trends Analysis Report By Biomarker (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs)), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

稀有生物標記檢體採集和穩定市場的成長和趨勢

根據 Grand View Research, Inc. 的新報告，全球稀有生物標記檢體收集和穩定市場規模預計到 2030 年將達到 923.9 億美元，2025 年至 2030 年期間的複合年成長率為 14.4%。循環稀有生物標記的潛在應用範圍不斷擴大，為致力於開發支援有效、快速收集和穩定這些稀有生物標記檢體的產品的技術開發人員創造了有利可圖的機會。此外，用於癌症篩檢、診斷、預後和治療監測的液態切片的出現大大增強了稀有生物標記檢體收集和穩定市場的競爭和能力，有助於收益成長。

由於循環生物標記有可能作為有價值的治療輸送系統和潛在的診斷劑，研究人員正在採用更靈敏、快速和靈活的分析工具。主要企業正在開發用於收集和穩定這些稀有生物標記檢體的新技術和產品，以擴大研究可能性。儘管具有相當大的優勢，臨床應用仍有挑戰需要克服。

許多分離方法具有高度特異性和敏感性，但迄今為止還沒有足夠的證據證明這些產品在臨床樣本中的使用和功效。這是因為這些方法之間的分析靈敏度的差異起著至關重要的作用，阻礙了稀有生物標記檢體的臨床使用。然而，對這些稀有生物標記檢體的臨床效用的研究不斷增加，有望有效解決與臨床實施相關的挑戰。

稀有生物標記檢體採集和穩定市場報告重點

  • 循環遊離 DNA（ccfDNA）部分在 2024 年佔據了最大的市場佔有率，為 36.0%。
  • 到 2024 年，研究部門將佔據最高佔有率，達到 74.1%。稀有生物標記領域的主導地位很大程度上歸因於越來越多的研究集中於其實施。
  • 預計到 2030 年，診斷領域將以 15.0% 的複合年成長率擴張。循環遷移細胞DNA（ccfDNA）、循環性腫瘤細胞（CTC）和外泌體等稀有生物標記主要用於研究環境，但在診斷應用的探索也日益增多。
  • 2024 年北美稀有生物標記檢體收集和穩定產業佔有 52.1% 的佔有率。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 稀有生物標記檢體採集和穩定市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 稀有生物標記檢體採集與穩定市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析

第 4 章 稀有生物標記檢體採集和穩定市場：生物標記的估計和趨勢分析

  • 2024 年及 2030 年生物標記市場佔有率
  • 細分儀表板
  • 利用生物標記採集和穩定全球稀有生物標記檢體的市場前景
  • 2018-2030 年市場規模、預測及趨勢分析
    • 循環遊離 DNA (ccfDNA)
    • 循環性腫瘤細胞(CTC)
    • 外泌體/細胞外囊泡
    • 循環遊離 RNA (ccfRNA)/miRNA

第 5 章 稀有生物標記檢體採集和穩定市場 - 按最終用途的估計和趨勢分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 細分儀表板
  • 全球稀有生物標記檢體採集和穩定市場前景（按最終用途）
  • 2018-2030 年市場規模、預測及趨勢分析
    • 研究
    • 診斷

第6章 稀有生物標記檢體採集與穩定市場：區域、估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 2024 年主要企業的市場佔有率分析
    • QIAGEN
    • Charles River Laboratories
    • F. Hoffmann-La Roche Ltd
    • Terumo Medical Corp
    • Thermofischer Scientific Inc
    • Eurofins Scientific
    • PerkinElmer Inc
    • Bio-Rad Laboratories, Inc
    • Agilent Technologies, Inc
    • Merck KGaA
    • Siemens Healthcare GmbH
Product Code: GVR-4-68038-459-8

Rare Biomarkers Specimen Collection And Stabilization Market Growth & Trends:

The global rare biomarkers specimen collection and stabilization market size is expected to reach USD 92.39 billion by 2030, expanding at a CAGR of 14.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding potential applications of circulating rare biomarkers has created lucrative opportunities for the technology developers that are engaged in the introduction of products to support the effective and rapid collection and stabilization of these rare biomarkers specimen. Furthermore, the emergence of liquid biopsy for cancer screening, diagnosis, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market for rare biomarkers specimen collection and stabilization, thereby aiding in revenue growth.

Given the potential of circulating biomarkers, both as high-value therapy delivery systems and as potential diagnostics, researchers are adopting more sensitive, rapid, and flexible analytical tools. Key players are developing novel technologies and products for collection and stabilization of these rare biomarkers specimen to expand research possibilities. Despite a substantial number of advantages, there are still challenges to overcome their clinical application.

Although most of the isolation methods are highly specific and sensitive, thus far, there is lack of sufficient evidence on the use and efficacy of the products in clinical samples. This hampers the clinical use of rare biomarkers specimen because differences in analytical sensitivity between these methods play a very crucial role. However, an increase in studies on the clinical utility of these rare biomarkers specimen is anticipated to effectively address the clinical implementation-related challenges.

Rare Biomarkers Specimen Collection And Stabilizations Market Report Highlights:

  • The circulating cell-free DNA (ccfDNA) segment accounted for the largest share of the market at 36.0% in 2024.
  • The research segment captured the highest share of 74.1% in 2024. The dominance of the rare biomarker segment is largely due to the growing number of research studies focused on their implementation.
  • The diagnostics segment expected to expand at the CAGR of 15.0% by 2030. While rare biomarkers such as Circulating Cell-Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and exosomes have primarily been used in research settings, they are increasingly being explored for diagnostic applications.
  • North America rare biomarkers specimen collection and stabilization industry dominated and accounted for a 52.1% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Biomarker
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Biomarker outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Rare Biomarkers Specimen Collection and Stabilization Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Demand for Precision Medicine
      • 3.2.1.2. Advancements in Liquid Biopsy Technologies
      • 3.2.1.3. Increasing Prevalence of Chronic and Genetic Diseases
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Costs
      • 3.2.2.2. Lack of Standardization
  • 3.3. Rare Biomarkers Specimen Collection and Stabilization Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Rare Biomarkers Specimen Collection and Stabilization Market: Biomarker Estimates & Trend Analysis

  • 4.1. Biomarker Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by Biomarker Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Circulating Cell Free DNA (ccfDNA)
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.2. Circulating Tumor Cells (CTCs)
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3. Exosomes/Extracellular Vesicles
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.2. By Product
        • 4.4.3.2.1. Isolation Kits & Reagents
          • 4.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.2.2. Blood Collection Tubes
          • 4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.2.3. Systems
          • 4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.3. By Specimen Type
        • 4.4.3.3.1. Serum/Plasma
          • 4.4.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.3.2. Others
          • 4.4.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.4. By Nucleic Acid & Other Biomolecules
        • 4.4.3.4.1. RNA
          • 4.4.3.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.4.2. DNA
          • 4.4.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.4.3. Others
          • 4.4.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5. By Application
        • 4.4.3.5.1. NIPT
          • 4.4.3.5.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.2. Oncology
        • 4.4.3.5.3. Market estimates and forecasts 2018 to 2030 (USD million)
          • 4.4.3.5.3.1. Research
            • 4.4.3.5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
          • 4.4.3.5.3.2. Diagnostics
            • 4.4.3.5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
            • 4.4.3.5.3.2.2. Screening
      • 4.4.3.5.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
            • 4.4.3.5.3.2.3. Treatment Monitoring
      • 4.4.3.5.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.4. Transcriptomics
          • 4.4.3.5.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.5. Pharmacogenomics
          • 4.4.3.5.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.6. Transplant Rejection
          • 4.4.3.5.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.7. Population Screening
          • 4.4.3.5.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.8. Cardiovascular Diseases
          • 4.4.3.5.8.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.9. Other Applications
          • 4.4.3.5.9.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.4. Circulating Cell Free RNA (ccfRNA) / miRNA
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.2. By Product
        • 4.4.4.2.1. Isolation Kits & Reagents
          • 4.4.4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.2.2. Blood Collection Tubes
          • 4.4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3. By Application
        • 4.4.4.3.1. NIPT
          • 4.4.4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.2. Oncology
          • 4.4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
          • 4.4.4.3.2.2. Research
            • 4.4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
          • 4.4.4.3.2.3. Diagnostics
            • 4.4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.3. Transcriptomics
          • 4.4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.4. Pharmacogenomics
          • 4.4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.5. Transplant Rejection
          • 4.4.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.6. Population Screening
          • 4.4.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.7. Cardiovascular Diseases
          • 4.4.4.3.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.8. Other Applications
          • 4.4.4.3.8.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 5. Rare Biomarkers Specimen Collection and Stabilization Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Research
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 5.4.1.2. Research Labs/CROs
        • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Academic Institutes
        • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Diagnostics
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Laboratories
        • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Hospitals
        • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.4. Prenatal clinics
        • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rare Biomarkers Specimen Collection and Stabilization Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.8.1.5. )
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company market share analysis, 2024
    • 7.3.2. QIAGEN
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Charles River Laboratories
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. F. Hoffmann-La Roche Ltd
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Terumo Medical Corp
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Thermofischer Scientific Inc
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Eurofins Scientific
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. PerkinElmer Inc
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Bio-Rad Laboratories, Inc
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Agilent Technologies, Inc
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Merck KGaA
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Siemens Healthcare GmbH
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 3 North America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 4 North America rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
  • Table 5 U.S. rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 6 U.S. rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 8 Canada rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 10 Mexico rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 12 Europe rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Europe rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
  • Table 14 Germany rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 15 Germany rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 17 UK rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 19 France rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 21 Italy rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 23 Spain rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Sweden rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 25 Sweden rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Norway rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 27 Norway rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Denmark rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 29 Denmark rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
  • Table 33 China rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 34 China rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Japan rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 36 Japan rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 37 India rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 38 India rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Australia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 40 Australia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 42 Thailand rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 43 South Korea rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 44 South Korea rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 46 Latin America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Latin America rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
  • Table 48 Brazil rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 49 Brazil rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 51 Argentina rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
  • Table 55 South Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 56 South Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 60 UAE rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
  • Table 62 Kuwait rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Rare Biomarkers Specimen Collection and Stabilization: Market outlook
  • Fig. 9 rare biomarkers specimen collection and stabilization competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 rare biomarkers specimen collection and stabilization market driver impact
  • Fig. 15 rare biomarkers specimen collection and stabilization market restraint impact
  • Fig. 16 rare biomarkers specimen collection and stabilization market strategic initiatives analysis
  • Fig. 17 rare biomarkers specimen collection and stabilization market: Biomarker movement analysis
  • Fig. 18 rare biomarkers specimen collection and stabilization market: Biomarker outlook and key takeaways
  • Fig. 19 rare biomarkers specimen collection and stabilization market: End Use movement analysis
  • Fig. 20 rare biomarkers specimen collection and stabilization market: End Use outlook and key takeaways
  • Fig. 21 Circulating Cell Free DNA (ccfDNA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Circulating Tumor Cells (CTCs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Exosomes/Extracellular Vesicles market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Isolation kits & reagents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Blood collection tubes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Serum/Plasma market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Nucleic acid & other biomolecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 NIPT market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Screening market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Treatment monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Pharmacogenomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Transplant rejection market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Population screening market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Circulating Cell Free RNA (ccfRNA) / miRNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Blood collection tubes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 NIPT market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Pharmacogenomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Transplant rejection market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Population screening market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Research labs/CROs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Prenatal clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Global rare biomarkers specimen collection and stabilization market: Regional movement analysis
  • Fig. 65 Global rare biomarkers specimen collection and stabilization market: Regional outlook and key takeaways
  • Fig. 66 North America rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 U.S. rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Canada rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Europe rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 UK rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Germany rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 France rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Italy rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Spain rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Sweden rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Norway rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Denmark rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Asia Pacific rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Japan rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 China rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 India rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Australia rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Thailand rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Korea rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Latin America rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Brazil rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Mexico rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Argentina rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Middle East and Africa rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 South Africa rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 UAE rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Kuwait rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)